The American Heart Association Data Grant on CKM Syndrome in Cancer Patients and Survivors funds analyses of real‑world data to quantify and address cardiovascular, kidney, and metabolic (CKM) disease in people with current or prior cancer. This cardio‑oncology initiative focuses on understanding prevalence, treatment patterns, and outcomes of CKM syndrome in cancer populations. Projects are expected to leverage large datasets such as electronic health records, registries, or claims databases.
Eligibility Criteria:
- Independent investigators at academic, clinical, or public‑health institutions worldwide.
- Proposals must focus on cancer patients or survivors and CKM disease (prevalence, management, shared risk factors, or outcomes).
- Multidisciplinary teams including oncology, cardiology, nephrology, epidemiology, and data science are encouraged.
- Ability to access and securely analyze suitable real‑world datasets.
Funding Details:
- AHA targeted research grant mechanism using large real‑world datasets.
- Budget and project duration follow AHA policies for this RFP; applicants propose a justified budget within program limits.
- Indirect costs are capped according to AHA rules stated in the current announcement.
Deadline:
- Letter of Intent deadline: January 19, 2026.
- Full application deadline (by invitation): March 23, 2026.
- Earliest project start date: August 1, 2026.
Where to go for further information: